You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Patients with HER2- stage II/III breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

Not yet recruiting
  • Breast Cancer
  • Cancer of the Breast
  • VENTANA MIB-1 Ki67 assay
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 18, 2023

Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer Trial in United States

Not yet recruiting
  • Anatomic Stage I Breast Cancer
  • +3 more
  • Endocrine Therapy
  • +7 more
  • Atlanta, Georgia
  • +4 more
Jun 15, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

Not yet recruiting
  • Invasive Breast Cancer
  • +4 more
  • Boston, Massachusetts
  • +1 more
Mar 20, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +20 more
  • Best Practice
  • +2 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Jan 5, 2023

HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 Trial in San Francisco (Neratinib,

Completed
  • HER2-positive Breast Cancer
  • +8 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Early Breast Cancer Trial (Ribociclib, Letrozole, Ansastrozole)

Not yet recruiting
  • Early Breast Cancer
  • (no location specified)
Apr 12, 2023

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer

Recruiting
  • Breast Cancer
  • Standard Therapy
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Jul 30, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Suspended
  • Anatomic Stage I Breast Cancer AJCC v8
  • +23 more
  • Short-Term Fasting
  • Chemotherapy
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 23, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Active, not recruiting
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +16 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Not yet recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +5 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jul 14, 2022

Breast Cancer, Breast Cancer Female, Breast Cancer, Male Trial in Tampa (biological, drug, procedure)

Recruiting
  • Breast Cancer
  • +7 more
  • Dendritic Cell Vaccine (DC1)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 23, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

Terminated
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Active, not recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +20 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.

Recruiting
  • Breast Cancer Female
  • +4 more
    • Ho Chi Minh City, Vietnam
    • +1 more
    Oct 16, 2023

    Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma Trial (drug,

    Not yet recruiting
    • Anatomic Stage II Breast Cancer AJCC v8
    • +3 more
    • (no location specified)
    Jan 24, 2023

    Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

    Recruiting
    • Anatomic Stage I Breast Cancer AJCC v8
    • +19 more
    • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 1, 2022

    Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States

    Recruiting
    • Breast Adenocarcinoma
    • +7 more
    • Multi-epitope HER2 Peptide Vaccine TPIV100
    • +5 more
    • Scottsdale, Arizona
    • +26 more
    Aug 17, 2022

    HER2-negative Breast Cancer, Advanced Solid Tumor Trial in Singapore (ADG106, Doxorubicin, Cyclophosphamide)

    Recruiting
    • HER2-negative Breast Cancer
    • Advanced Solid Tumor
    • Singapore, Singapore
      National University Hospital
    Jun 9, 2022

    Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

    Recruiting
    • Breast Neoplasms
    • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
    • Shenyang, Liaoning, China
      Shengjing Hospital affiliated to China Medical University
    Jul 30, 2022

    Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,

    Active, not recruiting
    • Estrogen Receptor Negative
    • +15 more
    • Bellevue, Nebraska
    • +3 more
    Nov 30, 2022

    Breast Tumors Trial (Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change

    Not yet recruiting
    • Breast Neoplasms
    • Chidamide combined with exemestane (+/- goserelin)
    • Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
    • (no location specified)
    Feb 15, 2022

    HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer Trial in Boston, Nashville (T-DM1, Pertuzumab, Excision of

    Active, not recruiting
    Has Results
    • HER-2 Positive Breast Cancer
    • +3 more
    • Boston, Massachusetts
    • +3 more
    Mar 4, 2022